Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Sumitomo Dainippon

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Sumitomo Dainippon 's Japan sales performance.

ds-pharma

A snapshot of… Exscientia

A snapshot of… Exscientia

We have so far discovered four preclinical drug candidates, and recently announced the first drug designed by AI in partnership with Sumitomo Dainippon Pharma to enter human trials.

Myovant preps US filing for relugolix in prostate cancer

Myovant preps US filing for relugolix in prostate cancer The positive trial result is also good news for Japanese drugmaker  Sumitomo Dainippon, which agreed a $3bn upfront deal to acquire a 45% stake in Myovant – and control of four other

Sumitomo Dainippon goes big on biotech with $3bn Roivant deal

Sumitomo Dainippon goes big on biotech with $3bn Roivant deal Could acquire up to 11 Roivant spinouts. Japanese pharma company Sumitomo Dainippon has announced a strategic deal with Roivant Sciences, a biotech holding company headed by entrepreneur Vivek Ramaswamy, for a ... Sumitomo Dainippon's expertise in

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease drug. The French company signed an agreement with Sumitomo Dainippon Pharma in 2017 for development rights to the drug in Asian markets including Japan, which has a slightly lower bar for

After Axovant shock, Roivant pens diabetes deal with Poxel

After Axovant shock, Roivant pens diabetes deal with Poxel The drug is already in phase III testing in Japan via a partnership with Sumitomo Dainippon Pharma, and Roivant will now take the lead on phase III trials in the US, ... Europe and other territories not covered by the Sumitomo alliance.

1 2 3 4 5 6 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics